Rivulet Media Inc (fka RIVU)

[PG]

First TEN Pages of Dr. Ichim's Resume (you know, the CSO of Regen. Please NOTE the Benitec connection below):

Thomas E Ichim
9255 Towne Centre Drive, #450, San Diego, CA 92121
Mobile: (858) 349 - 3617
Email: [e-mail]
Place of Birth: Kitchener, Ontario, Canada
PROFESSIONAL EXPERIENCE:
2012-Present President and Chief Scientific Officer
Medistem Inc
9255 Towne Centre Drive, Suite 450, San Diego, CA 92121
2008-2012 Chief Executive Officer and Chief Scientific Officer
Medistem Inc
9255 Towne Centre Drive, Suite 450, San Diego, CA 92121
2007-2008 Chief of Scientific Development
Medistem Inc
9255 Towne Centre Drive, Suite 450, San Diego, CA 92121
2006-2009 Chief Technology Officer
OncoMune LLC
18851 NE 29th Avenue, Suite 500, Aventura, FL 33180
2004-2007 Co-Founder and Program Manager
bioRASI LLC
18851 NE 29th Avenue, Suite 500, Aventura, FL 33180
2004-Present Managing Partner
Vendevia Group
18851 NE 29th Avenue, Suite 500, Aventura, FL 33180
2003-2004 Scientist
Department of Surgery, University of Western Ontario
1151 Richmond Street, London, ON N6A 3K7, Canada
2003-2005 Cofounder and CEO
MedVax Pharma Corp
126 Madison Ave South, Kitchener, Ontario, Canada
2002-Present Co-founder and Vice President of Business Development
ToleroTech Inc
84 Hesketh Street, London, Ontario, Canada2000-2003 Director of Regulatory Affairs
MarrowTech Pharma Inc
26 Carriage Hill Cres, London, Ontario, Canada
1999-2000 Research Assistant
Department of Microbiology and Immunology, University of
Western Ontario, 1151 Richmond Street, London, Ontario. Canada
1995-1997 President
Batu Centre for Leukemia Research
126 Madison Ave South, Kitchener, Ontario, Canada
1993-1994 Summer Student
University of Guelph, Guelph Ontario
MAJOR ACCOMPLISHMENTS/RESPONSIBILITIES:
At Medistem:
Discovered a new stem cell that is economical to manufacture and is non-embryonic
Obtained FDA approval for testing stem cell in patients (clinical trials)
Recruited internationally-renowned doctors (Mike Murphy Indiana University, first to
use stem cells for leg conditions in USA and Amit Patel University of Utah, first to use
stem cells in human heart in world) to perform the trials
Inventing 20 families of patents and patent applications in area of regenerative medicine
Recruiting former CEO of Juvenile Diabetes Research Foundation, Alan Lewis, to
become Medistem CEO
[b]Initiated and led collaborations with biotechnology companies (Benitec Biopharma,
Aethlon Medical, Entest Biomedical, Orcrist Bio) leading to scientific publications and
Federal SBIR grant
Initiated and led collaborations with international universities including: University of
Utah; University of California San Diego; Indiana University; National Institutes of
Health; Central South University, Changsha, China; Regenerative Medicine and Cell
Therapies Laboratory, CUCAIBA, Ministry of Health Argentina; University of Western
Ontario; University of Alberta; Institute for Molecular Medicine; Karelian Research
Center, Russian Academy of Sciences, Petrozavodsk, Russia;? Recruited Medistem’s Advisory Board including Dr. Hugh Taylor, Director of
Reproductive Biology at Yale University, and Dr Gene Ray, founder and CEO of Titan
which had a 2.6 Billion liquity event
? Published 67 peer reviewed scientific publications with Medistem
At Regen BioPharma:
? Assembled clinical development program with FDA application in preparation for
treatment of aplastic anemia
? Invented 2 patents for treatment of bone marrow disorders
? One peer reviewed manuscript accepted for publication
At OncoMune:
? Obtained issued patent # 8,263,571 covering means of treating cancer by blocking new
cancer-causing gene
Developed preclinical and clinical strategy, including 1 peer reviewed publication
At bioRASI:
Designed and executed clinical trials for assessing efficacy of novel interventions in
human subjects with specialization in stem cells/regenerative medicine
Assisted clients in publishing and patenting data
At Vendevia:
Performed scientific due diligence before investment/partnerships
Designed scientific/clinical development plan for portfolio companies
Worked with the Chief Scientific Officer to develop overall technology strategy for the
fund
At Dept Surgery, University of Western Ontario (Weiping Min Lab):
Laboratory research involving cell therapy and transplantation
Filed patents on first use of RNA interference for immune modulation
Published scientific papers and assisted in grant writing
At MedVax Pharma Corp:
Invented new cancer vaccine and filed patent application
Published peer-reviewed proof of concept manuscriptAt ToleroTech:
Invented new uses of RNA interference for organ transplant rejection
Demonstrated proof-of-concept in animal models and published in peer reviewed journals
Obtained Proof of Principle grant for Wei-Ping Min’s laboratory
At Marrowtech Pharma:
Compiled preclinical data and filed successful application to perform clinical trials using
stem cell generated cancer inhibitor
At Department of Microbiology and Immunology, University of Western Ontario:
Performed laboratory experiments using stem cell generated cancer inhibitor
At Batu Center for Leukemia Research:
Developed proposal for new stem cell based method of treating leukemia in collaboration
with Dr. Mark Minden
Organized and executed national fundraising campaign to fund leukemia research
At University of Guelph
Designed and executed research project assessing effects of antioxidants on porcine
lymphocyte proliferation
Presented results at the 4
th International Veterinary Immunology Symposium, Davis
CaliforniaEDUCATION:
1990 Canadian Securities Institute, Toronto, Canada
Canadian Options and Derivatives License
1998 University of Waterloo, Waterloo, Ontario, Canada
BSc in Biology
2003 University of Western Ontario, London, Ontario, Canada
MSc Microbiology and Immunology
2005 Society of Clinical Research Associates, Chalfont, PA
Certified Clinical Research Associate
2007 University of Sciences Arts and Technology, Olveston Monserrat
Ph.D Immunology
SCIENTIFIC ADVISORY BOARDS:
MyoStim Pacers, San Diego (2011-present)
Cromos Pharmaceuticals, Moscow (2010-present)
Orcrist Inc, Edmonton, Canada, Chairman (2008-2010)
Entest Bio, La Mesa, California (2010-2011)
BOARDS:
Creative Medical, Phoenix Arizona (2011-present)
Carbon Manna (2010-2011)
Riordan Clinic, Wichita, Kansas (2009-present)
Medistem Inc (2008-present)
SOCIETIES:
American Society for Transplantation (2002-2003)
Canadian Society for Immunology (2001-2003)
Biocom (2007)
PEER REVIEW AND JOURNAL ASSOCIATIONS:
Editor StemCellPatents.com (2007-2009)
Monitoring Editor for Journal of Translational Medicine (2009-present)
Editorial Board of Pharmaceutical Patent Analysis (2011-present)
Reviewer for:Cellular Immunology,
Journal of Translational Medicine,
Expert Opinion on Biological Therapy
Current Opinion on Molecular Therapeutics
HONORS AND AWARDS
2010 NIH Grant 1R43HL096213-01A1 Woods (PI), Ichim Co-PI $125,000
Therapeutic Angiogenesis by Universal Donor Endometrial Regenerative Cells
2008 Biomed Central Publication of the Year Award for 2007. ERC discovery paper
chosen as top publication out of 200 journals.
2004 International Congress of Immunology, Travel Award
2003 American Society for Transplantation, Young Investigator Award
2001 Maclean’s Magazine Honor Roll (National Merit Award for Top Ten Canadians;
awarded for fundraising and scientific contributions to cancer research in Canada)
2001 University of Western Ontario, Department of Microbiology and Immunology, Special
University Scholarship
2001 University of Western Ontario, Department of Microbiology and Immunology Graduate
Student Travel Award
2000 Canadian Society of Immunology Travel Award
1994 Gold medal awarded at Canada Wide Science Fair.
1994 4th Place at International Science and Engineering Fair.
1994 Ontario Scholar
BOOKS AND BOOK CHAPTERS
BOOK: Wei-Ping Min, Thomas Ichim. RNA Interference: From Biology to Clinical
Applications, Humana Press, 2010 - 450 pages
BOOK: Thomas Ichim, Christine Ichim. Immunological Control of Neoplasia. Rapoport
Publishing, Ontario Canada, 1998 – 112 pages
Amit N Patel, Ramasamy Sakthivel, Thomas E Ichim, Stem Cell Therapy for Heart Failure
Using Cord Blood. Chapter 23 in Regenerative Medicine Using Pregnancy-Specific BiologicalSubstances edited by Niranjan Bhattacharya and Phillip Stubblefield, Springer Press, 2011 – 453
pages
Neil H. Riordan, Thomas E. Ichim, Famela Ramos, Samantha Halligan, Rosalia De Necochea
Campion, Gzegorz W. Basak, Steven F. Josephs, Boris R. Minev, and Ewa Carrier. Tumor Stem
Cells: Therapeutic Implications of a Paradigm Shift in Multiple Myeloma. Chapter 20 in Cancer
Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting
Measures. Springer Press, 2011, 509
PUBLISHED ABSTRACTS
D Lian, M Li, TE Ichim, B Garcia, R Zhong, and Min W-P*. Induction of “infectious tolerance”
by dendritic cells derived from tolerant allo-cardiac transplant recipients. American J
Transplantation 2004, Supplement 8, Vol 4: 394.
M Li, D Lian, TE Ichim, R Zhong, and Min W-P*. In vivo immune modulation by in vitrogenerated tolerogenic dendritic cells in murine heart transplantation. American J Transplantation
2004, Supplement 8, Vol 4: 600.
Min W-P, D Lian, M Li, TE Ichim, B Garcia, and R Zhong. Synergistic infectious tolerance by
adoptive transfer of tolerogenic dendritic cells and regularity T cells. American J
Transplantation 2004, Supplement 8, Vol 4: 412.
Min W-P, TE Ichim, KP Kusznieruk, Li M, X Huang, X Yan and R Zhong. Modulation of
dendritic cell-mediated immune responses by RNA interference. The FASEB Journal 2003. 17
(7): C267.
TE Ichim, Li M, D Zhou, X Huang, X Yan, R Zhong and Min W-P*. Generation of tolerogenic
dendritic cells by inhibiting IKK activity. The FASEB Journal 2003. 17 (7): C313.
Li M, D Lian, D Zhou, H Wang, TE Ichim, X Huang, X Yan, R Zhong and Min W-P*. In vitro
generated suppressor dendritic cells and T regulatory cells prevent allograft rejection. The
FASEB Journal 2003. 17 (7): C114.
Hill JA., DP White, TE Ichim, KP Kusznieruk, X Xia, J Yang, R Zhong, E Cairns, DA Bell and
Min W-P. Novel mechanism of immune modulation through the use of small interfering RNA.
Arthritis Rheumat 2002. 46 (9):S563.
Min W-P, D Zhou, X Xia, TE. Ichim, X Zhang, J Yang, X Huang, B Garcia, P Dutartre, AM
Jevnikar, GH Strejan , R Zhong. The role of tolerogenic dendritic dells on regulatory T cells and
transplant tolerance. Transplantation 2002. 74 (4): 133.
Min W-P. T.E. Ichim, D. Zhou, N.Kanai, D. Lian,.B. Garcia, P. Dutartre, A.M. Jevnikar, G.H.
Strejan,B.Singh. Zhong, R. LF15-0195 and anti-CD45RB antibody induce tolerance through
dendritic cells with suppressive phenotype. The FASEB Journal 2002. 16 (5): A1034.